This Seminar is based on studies published during the past 5 years, although classic papers have also been cited. We searched PubMed and Embase for papers published between January, 2012, and March, 2018, using the search terms: “brain tumour”, “glioblastoma”, “glioma”, “astrocytoma”, “oligodendroglioma”, “ependymoma”, and “pilocytic astrocytoma” in combination with the terms: “risk factors”, “molecular”, “investigation”, “management”, “surgical resection”, “drug therapy”, “clinical trial”,
SeminarPrimary brain tumours in adults
Introduction
Primary brain tumours refer to a heterogeneous group of tumours arising from cells within the CNS. Gliomas represent 75% of malignant primary brain tumours in adults.1 Gliomas are tumours of neuroectodermal origin arising from glial or precursor cells, and include astrocytomas, oligodendrogliomas, and ependymomas. Their classification has undergone major restructuring in the 2016 version of the WHO classification of CNS tumours,2 with a subsequent effect on diagnostic criteria, diagnostic testing approaches, grading, prognosis, and treatment planning. The incorporation of both molecular and histological parameters into this revised classification, along with progress in genomics and in cancer and CNS immunology, has defined a new era in neuro-oncology.
This Seminar emphasises key changes in the current classification of gliomas, and also explores the main molecular markers and their clinical significance. We also review current standard-of-care management for the main adult gliomas subtypes, and provide a clinically focused summary of practice-changing clinical trials. Finally, we provide an overview of emerging treatments for gliomas.
Section snippets
Clinical presentation
Patients with primary brain tumours can present with focal (ie, related to a specific location in the brain) or generalised symptoms over days to weeks, or months to years, depending on the speed of growth and location of the tumour. Tumours can also be found by brain imaging that has been done for unrelated purposes.
Tumours in some functional areas of the brain will cause more obvious focal neurological deficits than in other areas, and tend to be discovered sooner on imaging. Frontal lobe
Epidemiology
The 2017 Central Brain Tumor Registry of the United States report provides a detailed discussion of brain tumour epidemiology.1 Primary brain tumours account for about 2% of all cancers, with an overall annual incidence of 22 per 100 000 population.1 Incidence increases with advancing age, and is highest in individuals older than 85 years. Nearly 80 000 new cases of primary brain tumours are expected in 2018 in the USA, of which one-third will be malignant.1 Meningiomas are the most common
Prognostic factors
Prognostic factors vary considerably by tumour type. Younger age, high performance status, lower tumour grade, and greater extent of resection are favourable prognostic factors for most adult primary brain tumours. Over the past decade, molecular genetic alterations have been recognised as more powerful prognostic and predictive markers than histological appearance alone (table 1).6, 14, 44, 45
Risk factors
Less than 5% of primary brain tumours are due to genetic predisposition syndromes (table 2), and most patients do not have identifiable risk factors. Ionising radiation is the only other uncontested risk factor for primary brain tumours.52, 53 No other environmental exposure or behaviour has been unequivocally identified.54 Of particular interest has been the potential association between cell phone use and risk of developing a brain tumour. Despite multiple large studies, no conclusive
Diagnostic investigations
In a patient with a suspected brain tumour, MRI with gadolinium is the investigation of choice (appendix). Additionally, multimodal MRI such as diffusion-weighted imaging and diffusion tensor imaging, MR perfusion, and MR spectroscopy are used to better characterise the tumour cellularity, vascularity, and metabolism, respectively, and can help distinguish tumour from non-neoplastic processes, including treatment effect.6, 62, 63, 64 CNS staging with craniospinal MRI is performed in selected
Surgical management
The initial treatment for most primary brain tumours is maximal safe resection, with goals of achieving an accurate histological diagnosis, establishing the tumour's molecular genotype, improving the quality of life, and increasing survival. Although there are no randomised controlled trials regarding the benefit of the extent of resection, the available evidence suggests that maximal safe resection improves functional status and reduces mortality in both low-grade65 and high-grade gliomas.6, 66
Upfront management by tumour type
In this Seminar, a treatment overview is provided for most frequent adult primary brain tumours (Figure 1, Figure 2). For additional details, the reader is referred to the National Comprehensive Cancer Network (NCCN)6 and the European Association For Neuro-Oncology (EANO) guidelines,7, 74 as well as referenced articles. Every effort should be made for a referral to a centre of excellence, which will afford both clinical trial participation6 and improved outcomes.
Management at recurrence
Pilocytic astrocytoma can progress as long as 25 years after surgery, especially when subtotally resected, but typically maintains its grade.76 Conversely, most diffuse low-grade gliomas and nearly all high-grade gliomas will eventually recur, and often transform into a higher grade.6 In the absence of positive phase 3 trials or level 1 evidence to guide treatment at progression or recurrence, all the above-mentioned options are used alone or in combination, and clinical trial participation is
Medical management
This section provides a brief overview on commonly encountered medical complications in glioma patients. For expanded discussion, the reader is referred to the NCCN6 and EANO guidelines.7, 74, 112
Future directions
Despite substantial progress over the past decade in revealing the molecular underpinnings of primary brain tumours, there remain few effective therapies. There are many possible reasons for this frustrating outcome: poor drug blood-brain barrier penetration, redundancy of intracellular signalling pathways, tumour molecular heterogeneity, and lack of validated biomarkers. Current experimental strategies include immunotherapy, targeted therapy, gene therapy, and novel drug-delivery technologies,
Outstanding research questions
Primary brain tumours remain difficult and challenging diseases to manage despite substantial progress in understanding their genesis. Further work is needed to understand the role of glioma stem cells in the origin of primary brain tumours and how the different modes of therapy may be used in such a setting. Even though very few trials have progressed to phase 3, recent advancements in immunotherapy, targeted and combination therapy show promise and provide hope. In addition, further analysis
Conclusion
Treatments and better outcomes for primary brain tumours have long lagged behind those of other tumours. However, a new era in neuro-oncology has emerged, with major advances in both cancer and CNS immunology, and progress in genomics. These rapid advances have created more therapeutic opportunities than ever before in neuro-oncology. It is likely that combinatorial regimens will be required to achieve a broad and durable antitumour benefit, and new advances in cell engineering technologies and
Search strategy and selection criteria
References (135)
- et al.
Headaches and brain tumors
Neurol Clin NA
(2014) - et al.
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Mod Pathol
(2015) - et al.
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas
Cancer Cell
(2013) - et al.
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Lancet Oncol
(2012) - et al.
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Lancet Oncol
(2012) - et al.
Neurofibromatosis type 1
Handb Clin Neurol
(2015) - et al.
Carcinogenicity of radiofrequency electromagnetic fields
Lancet Oncol
(2011) - et al.
Adult brain tumor imaging: state of the art
Semin Roentgenol
(2014) Intraoperative MRI and maximizing extent of resection
Neurosurg Clin N Am
(2017)- et al.
Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trial
Int J Radiat Oncol Biol Phys
(2004)
Surgical resection versus watchful waiting in low-grade gliomas
Ann Oncol
FK. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the extent of resectionTC 22845 randomised trial
Lancet
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (extent of resectionTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Lancet Oncol
Validation of extent of resectionTC Prognostic Factors for Adults with Low- Grade Glioma: a Report Utilizing Intergroup 86-72-51 1
Int J Radiat Oncol Biol Phys
A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844
Int I Radiat Oncol Bid Phys
Interim results from the CATNON trial (extent of resectionTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study
Lancet
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: extent of resectionTC brain tumor group phase 2 study 26972
Ann Oncol Off J Eur Soc Med Oncol
CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014
Neuro Oncol
Epilepsy in brain tumor patients
Curr Opin Neurol
Epilepsy associated tumors: review article
World J Clin Cases
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Rev Lancet Oncol
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
N Engl J Med
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402
J Clin Oncol
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of extent of resectionTC Brain Tumor Group Study 26951
J Clin Oncol
The 2016 World Health Organization classification of tumors of the central nervous System: a summary
Acta Neuropathol
Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location
Neuro Oncol
Management of diffuse low-grade gliomas in adults: use of molecular diagnostics
Nat Publ Gr
Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors
N Engl J Med
The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism
Int J Cancer
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations
Br J Cancer
TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas
Neuro Oncol
TERT promoter mutation and its interaction with IDH mutations in glioma_ Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups: a meta-analysis of aggregate data
Crit Rev Eukaryot Gene Expr
NOA-04 randomized phase III trial of tequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide
J Clin Oncol
Oligodendroglioma: pathology, molecular mechanisms and markers
Acta Neuropathol
Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice
Neuro Oncol
A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma
Cancer Res
Long-term analysis of the NOA-04 randomized phase 3 trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide
Neuro Oncol
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
Nat Genet
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Nature
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
Acta Neuropathol
The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
Genes Dev
Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail
Brain Pathol
Characterization of gliomas: from morphology to molecules
Virchows Arch
Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes
Acta Neuropathol
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
N Engl J Med
MGMT Gene silencing and benefit from temozolomide in glioblastoma
N Engl J Med
Short-course radiation plus temozolomide in elderly patients with glioblastoma
N Engl J Med
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase 3 clinical trial
J Clin Oncol
Cited by (899)
Glucose regulates the HMGB1 signaling pathway through SIRT1 in glioma
2024, Cellular SignallingShedding light on function of long non-coding RNAs (lncRNAs) in glioblastoma
2024, Non-coding RNA ResearchSelf-consuming DNA nanogear retrieval exosomes for grading analysis of gliomas
2024, Chemical Engineering JournalIntegrated proteogenomic characterization of glioblastoma evolution
2024, Cancer Cell